Search

everythinglearnresearchcommunity

for

Search:↓

LC-OCT can help identify lupus-related scarring hair loss by spotting unique features.

Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.

Mutations in the enzyme don't significantly change how it binds to its specific substances.

Syndecan-1 is essential for maintaining skin fat and preventing cold stress.

Selenosis in calves causes health issues and changes in blood parameters.

A rare skin condition in a baby showed unusual fat and hair follicle changes.

The document concludes that treatment improved skin lesions but not scalp hair loss in two patients with Graham-Little-Piccardi-Lassueur syndrome.

Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.

Cathepsin L deficiency causes hair and skin issues in mice.

Discoid Lupus Erythematosus often causes scarring hair loss, is influenced by genetics and environment, and requires early treatment to prevent worsening.

The method accurately and quickly measures silodosin and dutasteride in mixtures.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

An 18-year-old girl improved with treatment after being diagnosed with both Systemic Lupus Erythematosus and Celiac Disease.

The woman was diagnosed with lichen sclerosus, a rare skin condition, after initial misdiagnosis and ineffective treatments.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

Tacalcitol cream effectively and safely treated a rare skin condition called Lichen Spinulosus in two cases.

Papillon-Lefèvre Syndrome causes early tooth loss and skin issues, needing early dental diagnosis.

Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.

SCD1 inhibitors can cause skin issues in rodents.

Dogs with generalized discoid lupus erythematosus have similar symptoms to humans and need continuous treatment.

A 16-year-old boy with Castleman's disease and lupus was successfully treated and showed no recurrence.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.